Showing 1 - 7 results of 7 for search 'Yuki Akazawa', query time: 0.03s Refine Results
  1. 1
    Non‐small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune‐related adverse events in first‐line treatments with immune checkpoint inhibitors: A retrospective single‐center study

    Non‐small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune‐related adverse events in first‐line treatments with immune checkpoint inhibit... by Yuki Akazawa, Aki Yoshikawa, Masaki Kanazu, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori

    Published 2022-09-01
    Get full text
    Article
  2. 2
    Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report

    Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report by Tomoki Kuge, Fukuko Okabe, Yuji Yamamoto, Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori

    Published 2021-06-01
    Get full text
    Article
  3. 3
    EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib

    EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib by Reina Hara, Masaki Kanazu, Ami Iwai, Tomoki Kuge, Mikako Ishijima, Takeshi Uenami, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori

    Published 2021-05-01
    Get full text
    Article
  4. 4
    Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients with idiopathic pulmonary fibrosis and non‐small cell lung cancer: A retrospective cohort study

    Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients with idiopathic pulmonary fibrosis and non‐small cell lung cancer: A retrospective... by Yuji Yamamoto, Yukihiro Yano, Tomoki Kuge, Fukuko Okabe, Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Toshihiko Yamaguchi, Masahide Mori

    Published 2020-11-01
    Get full text
    Article
  5. 5
    Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

    Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316) by Motoko Tachihara, Shunichi Negoro, Takako Inoue, Motohiro Tamiya, Yuki Akazawa, Takeshi Uenami, Yoshiko Urata, Yoshihiro Hattori, Akito Hata, Nobuyuki Katakami, Soichiro Yokota

    Published 2018-10-01
    Get full text
    Article
  6. 6
    Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.

    Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. by Yukihiro Yano, Hiroyuki Kurebe, Ryuya Edahiro, Yuki Hosono, Saeko Nakatsubo, Kohei Nishida, Nobuyuki Sawa, Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Toshihiko Yamaguchi, Masahide Mori

    Published 2018-01-01
    Get full text
    Article
  7. 7
    Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)

    Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L) by Nobuyuki Yamamoto, Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba, Eriko Miyawaki, Junichi Shimizu, Tomohiro Ozaki, Daichi Fujimoto, Ryo Toyozawa, Atsushi Nakamura, Toshiyuki Kozuki, Kentaro Tanaka, Shunsuke Teraoka, Kazuhiro Usui, Kazumi Nishino, Osamu Hataji, Keiichi Ota, Noriyuki Ebi, Sho Saeki, Yuki Akazawa, Motoyasu Okuno, Kazuhiko Nakagawa

    Published 2020-05-01
    Get full text
    Article

Search Tools: